ADAGENE INC. - ADS EACH REPRESENTING 1.25 ORDINAR

Adagene to Participate in the Jefferies Virtual China Biotech Summit

21 Oct 2021 08:00:00 By Nasdaq GlobeNewswire

Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates

26 Aug 2021 07:45:00 By Nasdaq GlobeNewswire

Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab)

19 Aug 2021 07:00:00 By Nasdaq GlobeNewswire

Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board

12 Aug 2021 07:45:00 By Nasdaq GlobeNewswire

Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab)

22 Jul 2021 07:45:00 By Nasdaq GlobeNewswire

Adagene Announces Authorization of Share Repurchase Program up to US$20 Million

07 Jul 2021 07:45:00 By Nasdaq GlobeNewswire

Adagene Announces Inclusion in FTSE Russell Indexes

16 Jun 2021 07:45:00 By Nasdaq GlobeNewswire

Adagene Presents Clinical Data from NEObody™ Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual Meeting

19 May 2021 17:05:00 By Nasdaq GlobeNewswire

Adagene Presents Preclinical Data from Lead SAFEbody™ Program, ADG126, at the American Association for Cancer Research (AACR) Annual Meeting 2021

13 Apr 2021 07:45:00 By Nasdaq GlobeNewswire

Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates

31 Mar 2021 07:45:00 By Nasdaq GlobeNewswire

Adagene Announces Clinical Advancement for ADG116

29 Mar 2021 07:45:00 By Nasdaq GlobeNewswire

Adagene Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option

11 Feb 2021 10:08:31 By Nasdaq GlobeNewswire

Adagene Inc. Announces Pricing of Initial Public Offering

09 Feb 2021 09:00:13 By Nasdaq GlobeNewswire